L
Laurent A. Decosterd
Researcher at University of Lausanne
Publications - 284
Citations - 11404
Laurent A. Decosterd is an academic researcher from University of Lausanne. The author has contributed to research in topics: Population & Therapeutic drug monitoring. The author has an hindex of 50, co-authored 266 publications receiving 10288 citations. Previous affiliations of Laurent A. Decosterd include École Polytechnique Fédérale de Lausanne & University of Tokyo.
Papers
More filters
Journal ArticleDOI
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
Catia Marzolini,Amalio Telenti,Laurent A. Decosterd,Gilbert Greub,Jérôme Biollaz,Thierry Buclin +5 more
TL;DR: Treatment failure and CNS side-effects are associated with low and high efavirenz plasma levels, respectively, which strongly argues for dose adjustment on the basis of therapeutic drug monitoring to optimize treatment.
Journal ArticleDOI
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Jacques Fellay,Catia Marzolini,Emma R. Meaden,David Back,Thierry Buclin,Jean Philippe Chave,Laurent A. Decosterd,Hansjakob Furrer,Milos Opravil,Giuseppe Pantaleo,Dorota Retelska,Lidia Ruiz,Alfred H. Schinkel,Pietro Vernazza,Chin B. Eap,Amalio Telenti +15 more
TL;DR: The polymorphism MDR1 3435 C/T predicts immune recovery after initiation of antiretroviral treatment, which suggests that P-glycoprotein has an important role in admittance of antifiltration drugs to restricted compartments in vivo.
Journal ArticleDOI
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
Sandrine Ostermann,Chantal Csajka,Thierry Buclin,Serge Leyvraz,Ferdy J. Lejeune,Laurent A. Decosterd,Roger Stupp +6 more
TL;DR: This is the first human pharmacokinetic study on TMZ to quantify CSF penetration and systemic or cerebral exposures are not better predictors than the cumulative dose alone for both efficacy and safety.
Journal ArticleDOI
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
Margalida Rotger,Sara Colombo,Hansjakob Furrer,Gabriela Bleiber,Thierry Buclin,Belle L. Lee,Olivia Keiser,Jérôme Biollaz,Laurent A. Decosterd,Amalio Telenti +9 more
TL;DR: CYP2B6 genotyping may be useful to complement an individualization strategy based on plasma drug determinations to increase the safety and tolerability of EFV.
Journal ArticleDOI
Towards a new combination therapy for tuberculosis with next generation benzothiazinones
Vadim Makarov,Benoit Lechartier,Ming Zhang,João Neres,Astrid M. van der Sar,Susanne A. Raadsen,Ruben C. Hartkoorn,O. B. Ryabova,Anthony Vocat,Laurent A. Decosterd,Nicolas Widmer,Thierry Buclin,Wilbert Bitter,Wilbert Bitter,Koen Andries,Florence Pojer,Paul J. Dyson,Stewart T. Cole +17 more
TL;DR: Compared to BTZ043, PBTZ169 has improved potency, safety and efficacy in zebrafish and mouse models of tuberculosis (TB), and when combined with other TB drugs, it showed additive activity against M. tuberculosis in vitro except with bedaquiline (BDQ) where synergy was observed.